About 4 000 reports

MSU – Grand Rapids Biomedical Research Facility – Michigan - Construction Project Profile

9 pages • By World Market Intelligence Ltd

SynopsisThe "MSU – Grand Rapids Biomedical Research Facility – Michigan - Construction Project Profile" contains information on the scope of the project including project overview and location. The profile also details project ownership and funding, gives a full project description, as well as information on contracts, tendering...

60 75 48
Apr 2015

Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019

379 pages • By Axis Research Mind

REPORT DESCRIPTIONGlobal Market Watch:Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology...

3 768 4 710 3 014
Apr 2015

Global Irbesartan Industry Report 2015

148 pages • By QY Research Group

The Global Irbesartan Industry Report 2015 is a professional and in-depth study on the current state of the Irbesartan industry.The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Irbesartan market analysis is provided for the international markets...

2 240 2 800 1 792
Apr 2015

Serbia Pharmaceuticals and Healthcare Report Q2 2015

108 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: A demand for austerity measures and public sector cuts by the IMF and the ongoing privatisation of state-owned enterprises will push the Serbian government to reduce its fiscal expenditure. The national health insurance fund will be pressured into reining in its costs, and...

985 1 300 818
Apr 2015

Greece Pharmaceuticals and Healthcare Report Q2 2015

100 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Since the election of the Syriza party in early 2015, Greece has seen considerable escalation in both political and economic uncertainty. This will limit the implementation of reform in the health sector and exacerbate the already high operational risks borne by drugmakers....

985 1 300 818
Apr 2015

Ghana Pharmaceuticals and Healthcare Report Q2 2015

122 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Our outlook for Ghana's pharmaceutical and healthcare market is becoming increasingly bearish. The National Health Insurance Scheme is facing backlash from both drugmakers and service providers due to a lack of payments. Furthermore, we believe that the scheme will come under...

985 1 300 818
Apr 2015

Norway Pharmaceuticals and Healthcare Report Q2 2015

66 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Norway's epidemiological profile will continue to be attractive to manufacturers of medicines for non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, the burden of chronic conditions will only decrease slightly over the next 15 years....

985 1 300 818
Apr 2015

Italy Pharmaceuticals and Healthcare Report Q2 2015

96 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: SNS pharmaceutical expenditure will decline in 2015 - creating revenue pressures for drugmakers and pharmacies in Italy and increasing out-of-pocket costs for the population. In February 2015, it was announced that the public healthcare costs will be slashed by EUR2.6bn (USD2.9bn)...

985 1 300 818
Apr 2015

Iraq Pharmaceuticals and Healthcare Report Q2 2015

83 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Iraq's attractiveness as a pharmaceutical market is highly dependent on the security situation in the country. With the Islamic State (IS) negatively impacting healthcare access in the northern states, Iraq's pharmaceutical market appeal to foreign investors has weakened....

985 1 300 818
Apr 2015

Dr Abidi Pharmaceutical Co in Consumer Health (Iran)

2 pages • By Euromonitor International

Dr Abidi Pharmaceutical plans to maintain its position as a leading pharmaceutical producer by focusing on the introduction of more general use products. The company aims to strengthen its position in key areas such as analgesics and cough remedies by improving product quality and distribution.Euromonitor International Local Company...

115 153 102
Apr 2015

United States Off–Label Drugs Market & Forecast

67 pages • By Renub Research

Off–label prescribing of medicines is prevalent worldwide because it gives freedom to physicians to apply new therapeutic options based on the latest evidence. Although physicians may lawfully prescribe approved Drugs for any use consistent with available scientific data and proper medical practice, but unfortunately, this is done without...

960 1 200 768
Apr 2015

Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2015

80 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Despite Cambodia's aim towards universal health coverage, we highlight that financial sustainability will remain a key issue. Nevertheless we highlight that pharmaceutical firms will benefit from this.Headline Expenditure Projections- Pharmaceuticals: KHR910.8bn...

985 1 300 818
Apr 2015

Australia Pharmaceuticals and Healthcare Report Q2 2015

144 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Recent attempts by the Australian government to introduce cost saving changes to the Medicare program have been met with opposition. Most have now been shelved. With healthcare costs growing at a 'rapid and unsustainable rate', as reported by Health Minister Sussan Ley, the government...

985 1 300 818
Apr 2015

Indonesia Pharmaceuticals and Healthcare Report Q2 2015

148 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Generic drugs sales in Indonesia will continue to see significant growth as they remain favoured by both low per capita pharmaceutical spending and inadequate intellectual property protection in the country. This is further reinforced by a growing chronic disease burden led by cardiovascular...

985 1 300 818
Apr 2015

Venezuela Pharmaceuticals and Healthcare Report Q2 2015

119 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Venezuela's pursuit of autonomy in pharmaceutical production and its overall pharmaceutical market will continue to diminish its appeal for foreign drugmakers. As the country deals with one of the worst performing currencies in the world, multinational pharmaceutical companies will...

985 1 300 818
Apr 2015

India Pharmaceuticals and Healthcare Report Q2 2015

165 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: India's challenging intellectual property landscape will continue to drive innovative drugmakers to adopt risk mitigation strategies, including forming partnerships with Indian generic pharmaceuticals companies. We highlight that such collaborations will also boost the marketing efforts...

985 1 300 818
Apr 2015

Lithuania Pharmaceuticals and Healthcare Report Q2 2015

100 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: The deteriorating macro outlook for Russia will impact Lithuania's economy, with negative effects on fiscal planning and therefore the pharmaceutical and healthcare sectors. However, the centre-left government's partial reversal of austerity measures, raising of minimum wages and boosts...

985 1 300 818
Apr 2015

Kuwait Pharmaceuticals and Healthcare Report Q2 2015

108 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: While the persistence of lower oil prices will drive down national budgets and curtail some investment programmes, we maintain that the healthcare sector's perception as a critical source of economic diversification away from hydrocarbons in addition to public support, will continue...

985 1 300 818
Apr 2015

Switzerland Pharmaceuticals and Healthcare Report Q2 2015

100 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Switzerland's epidemiological profile will continue to be attractive to manufacturers of medicines for non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, the burden of chronic conditions will account for a large proportion of the total disease...

985 1 300 818
Apr 2015

Bangladesh Pharmaceuticals and Healthcare Report Q2 2015

99 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: The gap in the provision of medical services in Bangladesh provides a strong business opportunity for private healthcare providers to make a foray into the market and establish a first mover advantage. This is further affirmed by the persistent challenges facing the Bangladeshi government...

985 1 300 818
Apr 2015

South Africa Pharmaceuticals and Healthcare Report Q2 2015

124 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: The continued commitment of the South African government to boosting spending on healthcare will be the primary driver for the growth of the pharmaceutical market in 2015. Although lower oil prices will improve the consumer environment for lower cost medicines, rampant unemployment...

985 1 300 818
Apr 2015

Taiwan Pharmaceuticals and Healthcare Report Q2 2015

139 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical and healthcare investment, but is not without flaws. Weaknesses in the country's regulatory regime and drug pricing concerns will continue to deter multinational interest over our...

985 1 300 818
Apr 2015

Turkey Pharmaceuticals and Healthcare Report Q2 2015

122 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Turkey possesses all the key growth fundamentals for an attractive pharmaceutical sector, but heavy regulatory oversight will stifle growth over the short term. Over the longer term, we expect the regulatory burden to lessen and become more amenable to the sector. In...

985 1 300 818
Apr 2015

Malaysia Pharmaceuticals and Healthcare Report Q2 2015

141 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Commercial opportunities for private healthcare providers in Malaysia will be buoyed by the robust growth in the country's medical tourism industry. Driven by strong demand from Asia and the weakening currency, we highlight that this trend will also create revenue prospects...

985 1 300 818
Apr 2015

Morocco Pharmaceuticals and Healthcare Report Q2 2015

114 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: A new wave of drug price cuts in Morocco and the implementation of the final stage of its universal healthcare coverage programme will see an improvement in the population's access to medicines. While increasing access to medicines is positive for drugmakers, we highlight...

985 1 300 818
Apr 2015

Spain Pharmaceuticals and Healthcare Report Q2 2015

99 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: The Spanish economy has exited the crisis stage and will post relatively strong real GDP growth rates compared to most other major eurozone economies over the next few years. However, we believe government spending will have a negligible impact on growth over the next...

985 1 300 818
Apr 2015

Iran Pharmaceuticals and Healthcare Report Q2 2015

118 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. Despite not specifically targeting medicines, sanctions against Iran had dire consequences for the pharmaceutical sector,...

985 1 300 818
Apr 2015

Egypt Pharmaceuticals and Healthcare Report Q2 2015

131 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: Egypt's inclusion on PhRMA's Special 301 Submission for the second year running highlights that regulatory approval delays and a restrictive pricing policy are still issues being faced by innovative drugmakers operating in the country. The domestic production of generic...

985 1 300 818
Apr 2015

Slovakia Pharmaceuticals and Healthcare Report Q2 2015

120 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: In 2014, almost 2.47% of the country's GDP was spent on pharmaceuticals, as combined sales of prescription drugs and over-the-counter medicines - sold through pharmacies and hospitals at consumer prices - reached EUR1.85bn (USD2.46bn). Although total pharmaceutical and...

985 1 300 818
Apr 2015

Moldova Pharmaceuticals and Healthcare Report Q2 2015

87 pages • By Business Monitor International

Includes 3 FREE quarterly updatesBMI View: While short-term prospects for the Moldovan pharmaceutical market present limited opportunities for investors, long term opportunities in the region show great potential. With Moldovan relationships strengthening between China and Europe, the Pharmaceutical market is...

985 1 300 818
Apr 2015